Search

everythinglearnresearchcommunity

for

Search:↓

A woman's hair loss was initially mistaken for a common hair loss condition but was later found to be caused by breast cancer cells in her scalp.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.

No definitive link between finasteride and male breast cancer, but further research is needed.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

The document concludes that modern photo stories help represent and challenge how breast cancer affects women's identities and societal norms.

Finasteride use is not clearly linked to an increased risk of male breast cancer.

Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.

Scalp cooling reduces hair loss during chemotherapy but doesn't help hair regrow after.

Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.

Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.

The number of advanced breast cancer cases in women under 40 has increased, but the overall numbers are still low.

Alopecia neoplastica is hair loss from breast cancer spreading to the scalp.

Some breast cancer treatments, like taxanes, can cause long-term hair loss.

Localized breast cancer can affect skin and hair.

Oncoplastic breast surgery is more cost-effective than standard lumpectomy for large-breasted women despite being more expensive.

A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.

Flaxseed lignans may reduce breast cancer risk in women.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Tamoxifen increases the risk of lasting hair loss after chemotherapy despite scalp cooling.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

The Breast Utility Instrument was developed to assess quality of life in breast cancer patients.

An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.

Understanding breast cancer requires considering both medical advancements and social influences.

Antibodies help identify glycoproteins in normal skin and tumor cells.

Glibenclamide slows breast cancer cell growth by stopping cell division.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Docetaxel and paclitaxel for breast cancer can cause permanent, severe hair loss.